The link at the company webpage wasn't working for me.
I caught the median prior treatment data in the press release, but they generalized with respect to the specific drugs.
Given the level of info right now, FDA consistency would suggest that these data provide a sufficient package for approval. They also have a larger trial running which should satisfy the FDA's requirement that the accelerated approval be validated with another trial. Makes ONXX a little more interesting to follow.
Market Data 
Markets 
AI
